UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 HARROW, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

Corporate Participants Conference Call Participants Operator I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow. Thank you, operator. Good afternoon, and welcome to Harrow's third quarter 2023 earnings conference call. For a list and description of those risks and uncertainties, please see the Risk Factors section of the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or othe ...

H A R R O W * Your patients. Our purpose. Poised to become a top-tier U.S. ophthalmic pharmaceutical company. o Service 4,000+ monthly accounts of over 10,000 prescribers and institutions. Management utilizes Adjusted EBITDA, an unaudited financial measure that is not calculated in accordance with GAAP, to evaluate the Company's financial results and performance and to plan and forecast future periods. Investors are encouraged to review the Company's complete results of operations and additional information ...

Company Participants Conference Call Participants Operator I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow. Please go ahead. Thank you, operator. Good afternoon, and welcome to Harrow's second quarter 2023 earnings conference call. For a list and description of those risks and uncertainties, please see the Risk Factors section of the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name on exchange on which registered | | --- ...

The conference has now concluded. Thank you very much for attending today's presentation. You may now disconnect your lines, and have a great day. Company Participants Conference Call Participants Operator I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow. Please go ahead. Thank you, operator. Good afternoon, and welcome to Harrow's First Quarter 2023 Earnings Conference Call. Harrow's results may differ materially from those projected. Harrow ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow Health, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or othe ...

Jamie Webb - Director, Communications and IR Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer  Conference Call Participants Operator I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow. Thank you, Operator. Good afternoon. And welcome to HarrowÂ's fourth quarter and year end 2022 earnings conference call. For a list and description of those risks and uncertainties, please see the Risk Factors section of the companyÂ's m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or other jurisdiction of ...